- Home
- FEMY vs PHGE Comparison
FEMY vs PHGE Comparison
Compare FEMY & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- PHGE
- Stock Information
- Founded
- FEMY 2004
- PHGE 2015
- Country
- FEMY United States
- PHGE Israel
- Employees
- FEMY N/A
- PHGE N/A
- Industry
- FEMY Medical/Dental Instruments
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- PHGE Health Care
- Exchange
- FEMY Nasdaq
- PHGE Nasdaq
- Market Cap
- FEMY 24.9M
- PHGE 26.5M
- IPO Year
- FEMY 2021
- PHGE N/A
- Fundamental
- Price
- FEMY $1.01
- PHGE $0.75
- Analyst Decision
- FEMY Strong Buy
- PHGE Strong Buy
- Analyst Count
- FEMY 3
- PHGE 2
- Target Price
- FEMY $10.00
- PHGE $22.50
- AVG Volume (30 Days)
- FEMY 245.5K
- PHGE 151.9K
- Earning Date
- FEMY 11-12-2024
- PHGE 11-14-2024
- Dividend Yield
- FEMY N/A
- PHGE N/A
- EPS Growth
- FEMY N/A
- PHGE N/A
- EPS
- FEMY N/A
- PHGE N/A
- Revenue
- FEMY $1,260,643.00
- PHGE N/A
- Revenue This Year
- FEMY $135.27
- PHGE N/A
- Revenue Next Year
- FEMY $310.75
- PHGE N/A
- P/E Ratio
- FEMY N/A
- PHGE N/A
- Revenue Growth
- FEMY 15.33
- PHGE N/A
- 52 Week Low
- FEMY $0.73
- PHGE $0.62
- 52 Week High
- FEMY $2.40
- PHGE $8.55
- Technical
- Relative Strength Index (RSI)
- FEMY 34.33
- PHGE 36.37
- Support Level
- FEMY $0.98
- PHGE $0.67
- Resistance Level
- FEMY $1.18
- PHGE $0.81
- Average True Range (ATR)
- FEMY 0.08
- PHGE 0.09
- MACD
- FEMY -0.03
- PHGE 0.00
- Stochastic Oscillator
- FEMY 4.76
- PHGE 44.00
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.